JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Figure 5

CD8 E percentages according to JCV-DNA detection in biological samples and ROC analysis. (a) CD8 E percentages associated with JCV-DNA positive urine samples (JCVu+), JCV-DNA positive plasma samples (JCVp+), and JCV-DNA negative plasma and urine samples (JCV-DNA−) are shown: for JCVu+, 13.4%  , for JCVp+, 13.2%  , and for JCV-DNA−, 8.0%  . Data are represented as median [interquartile range]. Statistical analysis was performed using a one-way ANOVA test for nonparametrical data (Kruskal–Wallis, ). Dunnett’s posttest was performed comparing each group with JCV-DNA− group, and asterisks represent the level of statistical significance. (b) ROC analysis was performed using CD8 E percentages after stratification of samples according to JCV detection in plasma and/or urine in JCV-DNA+ and JCV-DNA−. The area under the curve is 0.73 with . The cut-off of >10.6% shows a sensitivity of 67% (CI: 51% to 80%) and a specificity of 65% (CI: 54% to 75%). CI: confidence interval. Lines and whiskers represent median values and interquartile ranges, respectively. CD8 E: CD8 effectors. ; ; ; .

(a)

(b)